AI Removes Blind Experimentation in Pharma, Not Experiments

AI is transforming early-stage drug discovery by replacing broad wet lab screening with computational methods that predict molecular behavior and identify disease targets. However, physical experimentation and clinical testing remain essential, preserving wet labs as critical validation and clinical trial points despite AI reducing the number of initial experiments.

This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and AI Frontier Models.